Related Experiment Videos
[On the problem of the cardiotoxicity of epirubicin-cisplatin]
W Lechner1, W Zechmann, P Mayr
1Universitäts-Klinik für Frauenheilkunde, Universitäts-Klinik für Nuklearmedizin, Innsbruck.
Abstract:
Cardiotoxicity is supposed to be the most important limiting factor in chemotherapy with anthracycline derivatives. The left ventricular ejection fraction was measured several times by means of radionuclid - scintigraphy in 24 patients treated with epirubicin - cisplatinum. Pathologic values have been found only in 3 patients, but no correlation with age, cumulative dose or dose/m2 of body surface could be demonstrated.